Literature DB >> 21411466

Long-term follow-up of renal function and blood pressure after selective renal arterial embolization.

C Scott Collins1, Christoph H Eggert, Anthony J Stanson, Vesna D Garovic.   

Abstract

PURPOSE: Renal arterial embolization is a minimally invasive alternative to the surgical treatment of certain renal diseases. The authors aimed to determine the safety of the procedure with respect to renal function and blood pressure control.
MATERIALS AND METHODS: This study was a retrospective review of the charts of patients who underwent therapeutic renal arterial embolization between January 1998 and December 2007. Indications for therapeutic renal artery embolizations included either treatment or prevention of renal hemorrhage. Exclusion criteria were total/ partial nephrectomy or dialysis prior to renal artery embolization and lack of appropriate follow-up.
RESULTS: A total of 115 procedures were reviewed, and 41 met the inclusion criteria. The mean age was 63 ± 18.87 years. Median follow-up was 13.0 months. The glomerular filtration rate (GFR) of the study population changed from 55.2 mL/min/1.73 m(2) at baseline to 56.63 mL/min/1.73 m(2) at last available follow up (P = .67). At baseline, 22 patients (53.7%) in this study group were hypertensive. Postprocedure, 9 patients required either the initiation of antihypertensive therapy or additional antihypertensive agents. Preexisting renal dysfunction (GFR < 30 mL/min/1.73 m(2)) at baseline did not appear to influence these outcomes.
CONCLUSIONS: Renal arterial embolization appears to be a safe procedure with respect to renal function. However, these patients should have close surveillance of their blood pressures to detect either the onset of hypertension or worsening of preexisting hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21411466     DOI: 10.1177/1531003510395605

Source DB:  PubMed          Journal:  Perspect Vasc Surg Endovasc Ther        ISSN: 1521-5768


  8 in total

1.  Spontaneous renal hemorrhage: critical analysis of different lines of management in non-traumatic patients: a single tertiary center experience.

Authors:  M A Elbaset; Mohamad H Zahran; Ramy El-Baz; Mohamed Badawy; Yasser Osman
Journal:  Int Urol Nephrol       Date:  2019-11-04       Impact factor: 2.370

Review 2.  Renal artery embolization-indications, technical approaches and outcomes.

Authors:  Arnaud Muller; Olivier Rouvière
Journal:  Nat Rev Nephrol       Date:  2014-12-23       Impact factor: 28.314

3.  Impact of Superselective Renal Artery Embolization on Renal Function and Blood Pressure.

Authors:  Hyoung Nam Lee; Seung Boo Yang; Dong Erk Goo; Yong Jae Kim; Woong Hee Lee; Dongho Hyun; Nam Hun Heo
Journal:  J Belg Soc Radiol       Date:  2020-11-06       Impact factor: 1.894

4.  Long term renal function following selective angioembolization for iatrogenic vascular lesions after partial nephrectomy: A matched case-control study.

Authors:  Ragheed Saoud; Nassib Abou Heidar; Joshua Aizen; Ciro Andolfi; Logan Galansky; Osmanuddin Ahmed; Arieh L Shalhav
Journal:  Investig Clin Urol       Date:  2021-03-25

5.  Management of acute post-operative hemorrhage following partial nephrectomy with renal artery embolization.

Authors:  Andrew T Gabrielson; Farzana A Faisal; Phillip M Pierorazio
Journal:  Urol Case Rep       Date:  2020-05-18

6.  Safety and efficacy of Endovascular Management of high-grade blunt renal injury.

Authors:  Bin Wang; Chongpei Wen; Songlin Song; Guilian Li; Yanggang Yan; Shoucai Cheng; Junmei Zeng; Zhidong Lin; Yong Wang
Journal:  J Interv Med       Date:  2022-02-26

7.  Renal artery embolization for managing uncontrolled hypertension in a kidney transplant candidate.

Authors:  Naji Alhamid; Hani Alterky; Mohammad Imad Othman
Journal:  Avicenna J Med       Date:  2013-01

8.  Value of Angioembolization in the Treatment of Iatrogenic Renal Vascular Injury Assisted by 3-Dimensional Digital Subtraction Angiography.

Authors:  Xin Liao; Hao Xu; Fan Liu; Xuli Min; Yugen Li; Lin Yang; Yongjun Ren
Journal:  Med Sci Monit       Date:  2020-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.